The latest health news highlights Britain's stance on the bioethanol industry, Berkshire Hathaway's investment moves, the FTC's probe into Hims & Hers, Scorpion Capital's position on Soleno ...

In recent years, men’s health has shifted from being a quiet, private matter to an open conversation fueled by technology and ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...

U.S. equities were mixed at midday following the release of the July retail sales report, which came in as expected.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

The disclosure in a filing Thursday gave a much-needed boost to the beleaguered health insurance giant, which saw shares jump as much as 9.6% in post-market trading. In other news: Nike co-founder ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Stock index futures rose on Friday, with Dow futures leading the charge, as UnitedHealth got a boost after Berkshire Hathaway ...